How projects we have funded will help us get more and better treatments to our community by June Kinoshita, FSHD Society Many of you have heard us describe the FSHD… Read More »
$3.4 million to speed us along our journey (Part 1)
Losmapimod continues to show promise
Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop… Read More »
Epic Bio takes aim at DUX4
Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Leading-edge CRISPR biotech chooses FSHD as its first disease target Epicrispr Biotechnologies, based in the San… Read More »
Corinne Bronfman, October 28, 1947 – October 7, 2022
She leaves a legacy of remarkable progress toward treatments for FSHD The FSHD Society was deeply saddened to learn of the passing of Corinne Bronfman on October7, in Washington DC…. Read More »
Roche announces Phase 2 trial in FSHD
The drug, GYM329, aims to boost muscle growth Roche, the Swiss pharmaceutical giant, has announced that it is launching an international Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD)…. Read More »